Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0000729 (abdominal cramps)
 531 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This is the first report of a phase I study with n-IL 2. N-IL 2 shows a higher biological activity and different immunomodulatory effects compared to recombinant IL 2. 14 patients (9 male, 5 female) entered our phase I study with continuous i.v. n-IL 2 with a median age of 40 years (range 4-65), including 4 children. The study design was a dose rising continuous iv infusion over 5 days with a starting dose of 1 x 10(6) U n-IL 2 up to 6 x 10(6) n-IL 2 over 24 h. In 2 of 16 regimen with n IL-2 there was a dose reduction and in 6 there was an interruption necessary. In 2 patients there was only a dose reduction necessary because of thrombocytopenia and hypotension. In 6 patients n-IL 2 had to break the continuous infusion. Reasons were an increasing BUN, respiratory insufficiency, thrombocytopenia, neurological symptoms and increasing liver enzymes. The 4 children developed an other side effect profile with edema of the face, abdominal cramps and thrombocytopenia. During the study no intensive care was necessary. The most common side effects were erythema, fever, nausea, dyspnea and hypotension. There was no complete remission, 21.5% of the patients had a partial remission, 7% showed no change and 71.5% had a progression. There were no significant differences in toxicity and response was comparable to studies using continuous r IL-2.
 ...
PMID:[Continuous infusion of natural interleukin 2 (n IL-2) in treatment of malignant diseases: phase I study]. 209 79

There are multiple potential states and/or symptoms that may occur in the palliative care population including: pain, nausea/vomiting, fatigue, anorexia, dyspnea, hiccups, cough, constipation, abdominal cramps/bloating, diarrhea, pruritis, depression/anxiety, dysphagia and sleep disturbances. Some of this may be the direct result of medications or drug-drug interactions from agents prescribed to treat the medical conditions that the patient has. Medication-related nausea and vomiting (MRNV) is a significant problem in palliative medicine that is reasonably common likely due to the multiple medications that these patients are often taking.
...
PMID:Medication related nausea and vomiting in palliative medicine. 2584 76

Introduction. Rabies is one of the most deadly infectious disease. We present a challenging case of an adverse reaction following rabies vaccine in a child. Case Summary. A 10-year-old girl was bitten by a stray dog in Bali and was prescribed rabies post-exposure prophylaxis. She developed breathlessness, abdominal cramps, and lips and eyes swelling 30 minutes after the second dose of rabies vaccine. The subsequent vaccine was successfully administered as a graded challenge with premedication. The final dose was administered in entirety under close observation. She developed transient hypotension 30 minutes later, which spontaneously resolved. Conclusion. There were multiple challenges in the care of this pediatric patient who was potentially exposed to rabies and experienced systemic adverse events during the course of post-exposure prophylaxis. A thorough clinical assessment should be made to weigh benefits versus risks of proceeding with rabies vaccination, bearing in mind that the disease is deadly.
 ...
PMID:A Case of Serious Adverse Reaction Following Rabies Vaccination. 3056 Jan 50

In July and August 1976, an outbreak of acute gastrointestinal illness occurred among persons who had consumed a commercially marketed soy protein tunafish salad extender. After a public warning of a possible product contamination, representatives of 350 households reported 508 persons ill with an afebrile gastrointestinal syndrome that occurred usually within 1 h after the salad-extender was eaten. Interviews of randomly selected reported ill persons (cases) showed that the principal symptoms were nausea (91%), abdominal cramps (71%), diarrhea (53%), headache (42%), difficulty breathing (36%), and vomiting (22%). A survey of persons in the community who had eaten tuna extender revealed an illness attack rate (5.1%), which was significantly higher than the background incidence of gastrointestinal illness (1.1%) in persons who did not eat the tuna extender (p < .05). A case-control study showed that significantly more cases than controls had a history of "allergy" (p < .02). Tests of the product prepared by the manufacturer with volunteers implicated texturized soy protein as the cause of the illness. The findings in this study demonstrated that consumption of textured soy protein may elicit an adverse gastrointestinal response in a small but significant number of individuals, especially those with a history of "allergy."
 ...
PMID:Gastrointestinal Illness Associated with Consumption of a Soy Protein Extender 1. 3082 65